江蘇索普(600746.SH):上半年淨利潤1.17億元,同比扭虧為盈
格隆匯8月19日丨江蘇索普(600746.SH)公佈2024年半年度報吿,報吿期實現營業收入31.93億元,同比增長30.98%;歸屬於上市公司股東的淨利潤1.17億元,同比扭虧為盈;歸屬於上市公司股東的扣除非經常性損益的淨利潤1.13億元;基本每股收益0.1011元。
公司堅持阿米巴管理模式引領,積極推進低成本戰略、精細化管理、持續技術改造、優化市場營銷等工作,堅守安全生產底線、生態環境紅線。因主要產品價格同比維持穩定、主要原料煤炭價格下降、主要裝置運行穩定、產銷量有較大增長、成本下降,今年上半年公司業績同比扭虧為盈。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.